Xencor Inc (NASDAQ:XNCR) major shareholder John S. Stafford III sold 1,000 shares of the stock in a transaction that occurred on Friday, September 14th. The shares were sold at an average price of $48.05, for a total transaction of $48,050.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

John S. Stafford III also recently made the following trade(s):

  • On Tuesday, July 10th, John S. Stafford III sold 50,293 shares of Xencor stock. The shares were sold at an average price of $39.89, for a total transaction of $2,006,187.77.
  • On Thursday, July 12th, John S. Stafford III sold 138,300 shares of Xencor stock. The shares were sold at an average price of $39.69, for a total transaction of $5,489,127.00.

Xencor stock traded down $0.04 during mid-day trading on Tuesday, reaching $45.47. 8,556 shares of the company traded hands, compared to its average volume of 190,177. Xencor Inc has a fifty-two week low of $18.97 and a fifty-two week high of $48.38. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -43.34 and a beta of 1.61.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Monday, August 6th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.48) by $0.02. Xencor had a negative net margin of 137.35% and a negative return on equity of 20.32%. equities research analysts anticipate that Xencor Inc will post -2.24 EPS for the current fiscal year.

A number of research analysts have issued reports on XNCR shares. BTIG Research started coverage on shares of Xencor in a research note on Monday, September 10th. They set a “buy” rating and a $56.00 price target on the stock. Piper Jaffray Companies restated an “overweight” rating on shares of Xencor in a research note on Tuesday, August 7th. BidaskClub lowered shares of Xencor from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. ValuEngine upgraded shares of Xencor from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, May 22nd. Finally, Zacks Investment Research upgraded shares of Xencor from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research note on Friday, August 10th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $40.38.

Large investors have recently added to or reduced their stakes in the company. Sei Investments Co. acquired a new stake in shares of Xencor in the second quarter worth $138,000. SG Americas Securities LLC acquired a new stake in shares of Xencor in the first quarter worth $115,000. Thompson Investment Management Inc. acquired a new stake in shares of Xencor in the second quarter worth $215,000. UBS Group AG increased its stake in shares of Xencor by 449.9% in the first quarter. UBS Group AG now owns 5,972 shares of the biopharmaceutical company’s stock worth $179,000 after acquiring an additional 4,886 shares during the period. Finally, Bank of Montreal Can acquired a new stake in shares of Xencor in the second quarter worth $232,000. Hedge funds and other institutional investors own 83.02% of the company’s stock.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

Featured Story: Should you buy a closed-end mutual fund?

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.